目的:探讨瑞舒伐他汀强化治疗对ACS患者PCI术后血脂代谢、脂肪细胞因子、斑块稳定性的影响。方法:选择在本院接受PCI治疗的106例ACS患者,回顾治疗方案并分为接受PCI术后瑞舒伐他汀常规剂量治疗的常规剂量组60例、接受PCI术后瑞舒伐他汀强化治疗的强化治疗组46例。对比两组患者治疗前后血脂代谢、脂肪细胞因子、斑块稳定性的差异。结果:PCI术前,两组患者的血脂代谢、脂肪细胞因子、斑块稳定性差异无统计学意义(P＞0.05)；PCI术后1月,强化治疗组患者外周血中脂质代谢指标HDL-C、ApoA1的含量高于常规剂量组,LDL-C、ApoB的含量低于常规剂量组；血清中脂肪细胞因子APN、Leptin的含量高于常规剂量组,Resistin的含量低于常规剂量组；斑块稳定性相关指标ICAM-1、MMP-1、TIMP-1的含量低于常规剂量组(P＜0.05)。结论:ACS患者PCI术后接受瑞舒伐他汀强化治疗,可有效调节机体脂质代谢并增加斑块稳定性。

Objective: To explore the effect of rosuvastatin intensification therapy on blood lipid metabolism, adipocytokines and plaque stability after PCI in ACS patients. Methods: ACS patients who received PCI in the hospital between July 2015 and January 2017were reviewed and divided into the routine dose group (n=60) who received rosuvastatin routine dose therapy after PCI and the intensification therapy group (n=46) who received rosuvastatin intensification therapy after PCI. The differences in blood lipid metabolism, adipocytokines and plaque stability were compared between the two groups before and after treatment. Results:Before PCI, the differences in blood lipid metabolism, adipocytokines and plaque stability were not statistically significant between the two groups (P>0.05). 1 month after PCI, lipid metabolism indexes HDL-C and ApoA1 levels in peripheral blood of intensification therapy group were higher than those of routine dose group while LDL-C and ApoB levels were lower than those of routine dose group; adipocytokines APN and Leptin levels in serum were higher than those of routine dose group while Resistin level was lower than that of routine dose group; plaque stability-related indexes ICAM-1, MMP-1 and TIMP-1 levels were lower than those of routine dose group (P<0.05). Conclusion: Rosuvastatin intensification therapy after PCI could effectively regulate the lipid metabolism and increase the plaque stability in ACS patients.

R541.4

邯郸市科学技术研究与发展计划项目资助(1623208102ZC)